on March 6, 2017

Jo, congratulations with this amazing achievement of your R&D team at Biogazelle. Tell us, why are you so excited about the work you have done? What we offer today is …

Read more

on March 24, 2016

The 'Survival Associated Mitochondrial Melanoma Specific ONcogenic RNA' is a long non-coding RNA that is specifically expressed in malignant melanoma cells, and not in other normal human cells or other …

Read more

on November 5, 2015

Exiqon A/S (NASDAQ OMX: EXQ), a leading provider of flexible solutions for RNA analysis, today announced the impressive results of a comparative study on technologies for functional knockdown. The study …

Read more

on October 20, 2015

MARLBOROUGH, Mass., Oct. 20, 2015 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering and developing innovative therapies primarily in the areas of dermatology and ophthalmology …

Read more

on October 15, 2015

Biogazelle NV today announced a research-stage collaboration with Isis Pharmaceuticals in which they will identify and validate novel targets to treat colon, liver and lung cancer, diseases with clear unmet …

Read more

on August 12, 2015

Biogazelle today announced that it has received €1.1M in funding from the agency for Innovation by Science and Technology (IWT) in Flanders to leverage its cancer therapy development program, focused …

Read more

on June 12, 2015

Biogazelle has a longstanding track record and internationally recognized expertise in RNA gene expression analysis, with a particular focus on non-coding RNA, such as microRNAs and long non-coding RNAs. Today, …

Read more

on February 6, 2015

On October 6, 2014, Biogazelle announced the closure of an investment round with QBIC Arkiv Fund, Foundation Majoie and SOFI to finance its growth (press release available on http://bgzlle.com/2bCDGtm). Today, Biogazelle …

Read more

on January 27, 2015

Biogazelle is a Ghent University spin-off company founded in 2007 by prof. Jo Vandesompele and dr. Jan Hellemans. With a proven track record in gene expression studies, Biogazelle is at …

Read more

on October 6, 2014

Qbic Arkiv Fund, Foundation Majoie and SOFI invest 2.0 million EUR in UGent spin-off Biogazelle, a company that offers software and laboratory services for gene expression analysis. Biogazelle will primarily …

Read more